DNMT1 and hematologic disorder: Spontaneous immunity against CT antigens can be introduced as a response to treatment with DNA methyltransferase (DNMT) inhibitors, such as 5-aza-2′-deoxycytidine (5-aza-2′-CdR) or 5-azacytidine [107, 108], which have been approved for treatment of hematologic malignancies and may also be useful for solid cancers.